The appointment of a new CFO is a significant event for a company. Given Witzeman's long-standing role within Chemed and his previous experience at Deloitte & Touche LLP, this transition is likely to be viewed positively by investors. His familiarity with the company's financials and strategic direction could lead to a smooth transition and potentially positive financial management, which might be reflected in the company's stock price in the short term.